

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an Assistant Commissioner for Patents, on May 22, 2002 Washington, D.C. 20231 on

Name of Attorney or Agent

Michael J. Hayden

Signature of Attorney or Agent

CAP&G Case 86 BM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE OF COMPANY

:

In the application of

Patrick J. Allen et al.

Serial No. 10/078,826

Group Art Unit 3761

Filed February 19, 2002

Examiner

Absorbent Article Having A Fever Indicator

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. П 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. [X] 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1^{st} O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

4. [] 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

- 5. [] <u>Information to be Considered with CPA Filing</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).
- 6. [] 37 C.F.R. §1.97(c) with fee payment (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ___, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

[X] (2) Copies of the cited documents are enclosed.

Г	-				
ı		A dditional	information.	: ~	attaalaad
ı		Auditionai	information	15	attached.

Respectfully submitted,

Michael P. Hayden Agent for Applicant(s) Registration No. 48,433

(513) 626-5800

Customer No. 27752

(IDS.doc) (Last Revised 12/7/01)

COPENDING APPLICATIONS

Atty. Docket No.	Serial Number	Inventor(s)	Filing Date
7538	09/342,308	Donald C. Roe	June 29, 1998
7538C	09/523.078	Donald C. Roe	March 10, 2000

MAY 2 8 2002

Approved for use through 10/31/2002 ON B 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE llection of information unless it contains a valid OMB course number

Under the Paperwork Reduction Act of 1995, no persor

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

a to a concection of information unless	7 -	- 2				
COMPLETE IF KNOWN 3 2000						
Application Number	10/078,826/NOLO	37.0-				
Confirmation Number	6590	OENTER R370				
Filing Date	February 19, 2002					
First Named Inventor	Patrick J. Allen					
Group Art Unit	3761					
Examiner Name						
Attorney Docket Number	8613M					
Filing Date First Named Inventor Group Art Unit Examiner Name	Patrick J. Allen 3761	TY GENTER FI3;				

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-3,998,098	12/21/1976	Chilton	
		US-4,232,552	11/11/1980	Hof et al.	
		US-4,345,470	08/24/1982	Hof et al.	
		US-4,408,905	10/11/1983	Ehrenkranz	
		US-4,457,253	07/03/1984	Manske	
		US-4,564,299	01/14/1986	Ehrenkranz	
		US-5,094,545	03/10/1992	Larsson et al.	
		US-5,174,656	12/29/1992	Dotan	
		US-5,222,809	06/29/1993	Ehrenkranz	1
		US-5,232,552	08/03/1993	Lundberg et al.	
		US-5,416,469	05/16/1995	Colling	
		US-5,468,236	11/21/1995	Everhart et al.	
		US-6,342,037	01/29/2002	Roe et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DO Country Code ³ Number ⁴	CUMENT Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T⁵
_		WO 00/00148 A1		01/06/2000	Procter & Gamble		
		WO 00/00233 A1		01/06/2000	Procter & Gamble		
	<u> </u>	WO 01/54552 A1		08/02/2001	Procter & Gamble		
		WO 01/65263 A2		09/07/2001	Procter & Gamble		
	1	WO 00/65348 A2		11/02/2000	Procter & Gamble		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹				
EXAMINE	R	DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.